KUALA LUMPUR, Feb 16 AstraZeneca today delivered a further 1,365,200 doses of Covid-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) to Malaysia, marking the successful completion of its commitment to supply 6.4 million doses under the Advanced Purchase Agreement with the Malaysian.
(FILES) An undated handout picture released by the University of Oxford on November 23, 2020 shows a vial of the University’s COVID-19 candidate vaccine, known as AZD1222, co-invented by the University of Oxford and Vaccitech in partnership with pharmaceutical giant AstraZeneca. – Britain on December 30, 2020 became the first country in the world to approve the coronavirus vaccine developed by drug firm AstraZeneca and Oxford University, with a mass rollout planned from January 4, 2021. (Photo by John Cairns / University of Oxford / AFP) /
The Presidential Tasks Force (PTF) on COVID-19 has insisted that the Oxford-AstraZeneca COVID-19 vaccine is safe for Nigerians despite the growing global concerns over possible side effects.
SunStar
Photo from the Philippine Information Agency
+ March 10, 2021 AROUND 20,000 doses of the AstraZeneca vaccine against Covid-19 were delivered to Davao Region on Wednesday morning, March 10, 2021, a week after the first batch of vaccines arrived in the region.
The Oxford-AstraZeneca s Covid-19 vaccine, allocated by the National Government, arrived around 7 a.m. via commercial flight at the Francisco Bangoy International Airport, also known as Davao International Airport.
This is on top of the 33,600 Sinovac CoronaVac vaccines, also allocated by the national government, delivered on March 2 and 4.
The arrival of the AstraZeneca in Davao came after nearly 500,000 doses arrived in Manila on March 4, making it the second Covid-19 vaccine to reach the Philippines after the 600,000 doses of Sinovac vaccine donated by China arrived on February 28.
COVID-19 vaccination begin at slow pace over vaccine, syringe shortage in Japan
Since the campaign began three weeks ago, just under 46,500 doses had been administered to frontline medical workers as of Friday
Reuters | March 8, 2021 | Updated 12:25 IST
Clinical trials in Japan for AstraZeneca and Moderna s vaccines have been conducted and the vaccines are now awaiting regulatory approval
Japan s COVID-19 inoculation campaign is moving at a glacial pace, hampered by a lack of supply and a shortage of specialty syringes that underscore the enormous challenge it faces in its aim to vaccinate every adult by the year s end. Since the campaign began three weeks ago, just under 46,500 doses had been administered to frontline medical workers as of Friday.
The Anglo-Swedish drugmaker worked with Oxford to develop one of the first COVID-19 vaccines authorised for widespread use. AstraZeneca said it hopes to cut the time needed to produce large amounts of any new vaccine to between six and nine months